ES2831673T3 - Estimulador de la función genital, sexual y reproductiva - Google Patents
Estimulador de la función genital, sexual y reproductiva Download PDFInfo
- Publication number
- ES2831673T3 ES2831673T3 ES10783644T ES10783644T ES2831673T3 ES 2831673 T3 ES2831673 T3 ES 2831673T3 ES 10783644 T ES10783644 T ES 10783644T ES 10783644 T ES10783644 T ES 10783644T ES 2831673 T3 ES2831673 T3 ES 2831673T3
- Authority
- ES
- Spain
- Prior art keywords
- pro
- sexual
- patients
- heptapeptide
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001568 sexual effect Effects 0.000 title description 70
- 230000001850 reproductive effect Effects 0.000 title description 23
- 210000004392 genitalia Anatomy 0.000 title description 8
- JTDTXGMXNXBGBZ-YVHUGQOKSA-N (2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@H](C(=O)NCC(=O)N2[C@@H](CCC2)C(O)=O)CCC1 JTDTXGMXNXBGBZ-YVHUGQOKSA-N 0.000 claims abstract description 39
- 108010046399 TP 7 Proteins 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 201000001880 Sexual dysfunction Diseases 0.000 claims abstract description 14
- 231100000872 sexual dysfunction Toxicity 0.000 claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 13
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 11
- 230000035946 sexual desire Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 1
- 230000036299 sexual function Effects 0.000 description 48
- 230000000694 effects Effects 0.000 description 47
- 241000700159 Rattus Species 0.000 description 28
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 18
- 230000006870 function Effects 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 230000035935 pregnancy Effects 0.000 description 13
- 230000007170 pathology Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000037007 arousal Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 238000005461 lubrication Methods 0.000 description 7
- 206010063659 Aversion Diseases 0.000 description 6
- 208000000509 infertility Diseases 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 231100000535 infertility Toxicity 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 230000002787 reinforcement Effects 0.000 description 5
- 230000003014 reinforcing effect Effects 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 102400000050 Oxytocin Human genes 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000010539 reproductive behavior Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000027326 copulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000009297 electrocoagulation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 230000003370 grooming effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010024421 Libido increased Diseases 0.000 description 1
- 229940117029 Melanocortin receptor agonist Drugs 0.000 description 1
- 206010027295 Menometrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000000336 melanocortin receptor agonist Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-MQYCRUOZSA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1C(CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-MQYCRUOZSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009121281/15A RU2404793C1 (ru) | 2009-06-04 | 2009-06-04 | Стимулятор половой, сексуальной и репродуктивной функции |
| PCT/RU2010/000285 WO2010140926A1 (ru) | 2009-06-04 | 2010-06-01 | Стимулятор половой, сексуальной и репродуктивной функции |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2831673T3 true ES2831673T3 (es) | 2021-06-09 |
Family
ID=43297916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10783644T Active ES2831673T3 (es) | 2009-06-04 | 2010-06-01 | Estimulador de la función genital, sexual y reproductiva |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8883741B2 (enExample) |
| EP (1) | EP2465521B1 (enExample) |
| JP (1) | JP5643816B2 (enExample) |
| CN (1) | CN102481335B (enExample) |
| BR (1) | BRPI1011071B8 (enExample) |
| CA (1) | CA2764351C (enExample) |
| ES (1) | ES2831673T3 (enExample) |
| RU (1) | RU2404793C1 (enExample) |
| WO (1) | WO2010140926A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2404793C1 (ru) | 2009-06-04 | 2010-11-27 | Общество с ограниченной ответственностью Био Пептид | Стимулятор половой, сексуальной и репродуктивной функции |
| RU2507212C3 (ru) * | 2012-03-28 | 2022-05-04 | Общество С Ограниченной Ответственностью "Айвикс" | Способ получения рекомбинантного пептида и полученный пептид |
| CN113413456A (zh) * | 2013-05-28 | 2021-09-21 | Ovb(爱尔兰)有限公司 | 用于生产重组肽的方法及所得到的肽 |
| US9717903B1 (en) | 2015-03-17 | 2017-08-01 | Gary Barrett | Electronic process to restore, improve and/or strengthen the libido; method to mend the sex drive in males and females |
| RU2626002C1 (ru) * | 2016-10-24 | 2017-07-21 | Общество С Ограниченной Ответственностью "Айвикс" | Новая группа пептидов для лечения женской сексуальной дисфункции |
| RU2655763C2 (ru) * | 2016-10-24 | 2018-05-29 | Общество С Ограниченной Ответственностью "Айвикс" | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций |
| JP2018118973A (ja) * | 2018-02-23 | 2018-08-02 | アイビックス・リミテッドＩｖｉｘ Ｌｔｄ． | 組換えペプチドを生産するための方法および得られるペプチド |
| JP6858227B2 (ja) * | 2019-07-11 | 2021-04-14 | アイビックス・リミテッドＩｖｉｘ Ｌｔｄ． | 組換えペプチドを生産するための方法および得られるペプチド |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU1124544C (ru) * | 1983-06-30 | 1995-01-09 | Институт молекулярной генетики РАН | Гептапептид, обладающий свойствами психостимулятора пролонгированного действия с иммунотропной активность |
| RU2058791C1 (ru) | 1989-01-11 | 1996-04-27 | Государственное предприятие "Элер-микро" | Стимулятор репродуктивной способности у теплокровных животных |
| US5872100A (en) | 1990-05-11 | 1999-02-16 | Deghenghi; Romano | Peptides containing D-2-Alkyl-Tryptophan |
| JP3204510B2 (ja) | 1993-04-05 | 2001-09-04 | コンペティティブ テクノロジーズ，インク． | 勃起不全の診断および治療 |
| US5932548A (en) | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| RU2155065C1 (ru) | 1999-04-23 | 2000-08-27 | Институт молекулярной генетики РАН | Анксиолитическое средство и фармацевтическая композиция анксиолитического действия |
| US6211156B1 (en) | 1999-11-10 | 2001-04-03 | Asta Medica A.G. | Peptides for treatment of erectile dysfunction |
| RU2252779C1 (ru) * | 2003-09-23 | 2005-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Способ профилактики и лечения язв желудочно-кишечного тракта |
| RU2290195C1 (ru) * | 2005-04-21 | 2006-12-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями |
| RU2317099C1 (ru) * | 2006-08-29 | 2008-02-20 | Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" | Лечебно-профилактическое средство для восстановления нарушений половых функций, способ получения масла зародышей пшеницы и способ получения концентрата масла зародышей пшеницы для восстановления нарушений половых функций |
| CN101302246B (zh) * | 2007-05-09 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 |
| RU2404793C1 (ru) | 2009-06-04 | 2010-11-27 | Общество с ограниченной ответственностью Био Пептид | Стимулятор половой, сексуальной и репродуктивной функции |
| EA013948B1 (ru) | 2009-06-08 | 2010-08-30 | Общество С Ограниченной Ответственностью "Витанта" | Средство, активирующее половую функцию |
-
2009
- 2009-06-04 RU RU2009121281/15A patent/RU2404793C1/ru active IP Right Revival
-
2010
- 2010-06-01 CN CN201080033918.6A patent/CN102481335B/zh active Active
- 2010-06-01 CA CA2764351A patent/CA2764351C/en active Active
- 2010-06-01 EP EP10783644.7A patent/EP2465521B1/en active Active
- 2010-06-01 BR BRPI1011071A patent/BRPI1011071B8/pt active IP Right Grant
- 2010-06-01 ES ES10783644T patent/ES2831673T3/es active Active
- 2010-06-01 JP JP2012513900A patent/JP5643816B2/ja active Active
- 2010-06-01 WO PCT/RU2010/000285 patent/WO2010140926A1/ru not_active Ceased
- 2010-06-01 US US13/376,023 patent/US8883741B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2764351A1 (en) | 2010-12-09 |
| CN102481335A (zh) | 2012-05-30 |
| BRPI1011071B1 (pt) | 2020-10-20 |
| US8883741B2 (en) | 2014-11-11 |
| EP2465521A1 (en) | 2012-06-20 |
| CA2764351C (en) | 2016-08-16 |
| BRPI1011071A2 (pt) | 2016-09-27 |
| EP2465521B1 (en) | 2020-10-14 |
| US20120129791A1 (en) | 2012-05-24 |
| CN102481335B (zh) | 2014-02-26 |
| JP5643816B2 (ja) | 2014-12-17 |
| JP2012528856A (ja) | 2012-11-15 |
| WO2010140926A1 (ru) | 2010-12-09 |
| RU2404793C1 (ru) | 2010-11-27 |
| BRPI1011071B8 (pt) | 2021-05-25 |
| EP2465521A4 (en) | 2012-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2831673T3 (es) | Estimulador de la función genital, sexual y reproductiva | |
| VM et al. | Female infertility and its treatment by alternative medicine: a review | |
| Tilt | A Handbook of uterine therapeutics and of diseases of women | |
| Amador et al. | A guide and resource directory to male fertility following spinal cord injury/dysfunction | |
| Kumar et al. | Therapeutic Management of Incomplete Cervical Dilatation in a Buffalo: A Case Report | |
| RU2612832C1 (ru) | Способ создания стойкого венозного полнокровия в малом тазу у лабораторных животных | |
| Danappagoudar et al. | Effective Ayurvedic management of Infertility due to low AMH in Elderly Women-Case Study | |
| Rosenthal et al. | Treatment of Trichomonas Vaginitis with Concentrated Salt Solution | |
| Dimitriadis et al. | 590 Employment of avanafil in a surrogacy program | |
| Gruaz et al. | Pregnancy toxemia, dystocia and uterine prolapse observed in does at the end of the gestation period | |
| Dikmen et al. | 613 Best with daily tadalafil in terms of lower urinary tract symptoms: What is the current situation among Turkish men? | |
| RU2578478C1 (ru) | Способ профилактики преждевременных родов | |
| Botta et al. | BEST PRACTICE IN VULVODYNIA—AN EVIDENCE-BASED LITERATURE REVIEW | |
| RU2480225C1 (ru) | Способ лечения воспалительных заболеваний половой сферы у женщин | |
| Konek | A Clinical Study of Homoeopathic Management in Uterinr Fibroid | |
| Kulkarni et al. | Clinical evaluation of leeching and surgical excision in the management of external thrombosed haemorrhoids | |
| WARD | TRANSACTIONS OF THE NEW YORK OBSTETRICAL SOCIETY | |
| Toohey | Sterility in the human male and female | |
| Brackett et al. | Male Fertility Following Spinal Cord Injury: A Guide For Patients | |
| Wood | The patient, boy aged nine years, was operated on in King’s | |
| Hanks | ON THE CAUSES AND TREATMENT OF EXCESSIVE OR UNUSUAL UTERINE HEMORRHAGES, WITH ILLUSTRATIVE CASES | |
| EHTOME | Nov. 19, igro | |
| Clark | The Efficacy of the homoeopathic simillimum in the treatment of endometriosis | |
| BURNS | FALSE LABOR PAINS. | |
| Wallace | Excision of the Uterus by the Vaginal (Three Cases) and Laparo-Vaginal Methods (One Case) for Cancer |